Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Approves Pfizer's Trastuzumab Biosimilar

Mar 12 2019

• By David Wallace

PfizerSign — Pfizer Has Received A US Nod For Its Trazimera Rival To Herceptin • Source: Shutterstock

Related Content

Further Victory For Celltrion and Teva, As Their Trastuzumab Biosimilar, Herzuma, Receives FDA Approval

Dec 17 2018

Amgen handed CRL on trastuzumab in US

Jun 09 2018

Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist

Jan 30 2019

Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal

Dec 09 2018

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

Jan 15 2019

Samsung Bioepis’ Trastuzumab Biosimilar Is Third Cleared By FDA – But The Market Hasn’t Formed Yet

Jan 21 2019

Additional Topics

Biosimilars Regulation Strategy

More from Biosimilars

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window